BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory

Genuity Science (acquired by HiberCell)

Genuity Science logo

Founded
2013
Patents
4
Publications
38

Technologies

AI Companies (Drug Discovery)

Our products and services span study design, cohort sourcing, sample preparation, sequencing, secondary and tertiary analysis, storage (including cloud-based), interpretation, scalable analytics, and AI applied to genotypic and phenotypic data. All of these activities are built upon the proprietary GOR data platform and supported by the analysis of our expert team.

Our products and services span study design, cohort sourcing, sample preparation, sequencing, secondary and tertiary analysis, storage (including cloud-based), interpretation, scalable analytics, and AI applied to genotypic and phenotypic data. All of these activities are built upon the proprietary GOR data platform and supported by the analysis of our expert team.

More detail on our Artificial Intelligence Capabilities led by Dr Tom Chittenden:

- AI Specific to Biology: WuXi NextCODE ensemble AI approach is purpose-built and customizable to answer specific biological questions. Other companies use algorithms built in other fields which leads to information loss in the analysis and limits findings to mere correlations, rather than causation.

- Biological Validation of AI outputs: WuXi NextCODE biologically validates BVAI outputs in vitro and in mice to confirm the findings. Studies, including the recent Nature paper, show that our BVAI approach accurately predicts disease biology.

- Causal Dependency and NLP validation: WuXi NextCODE BVAI approach uses probabilistic programming to infer what bioprocesses cause downstream phenotypes, thus giving a clearer picture of potential drug targets and biomarkers.

genomics drug discovery